Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 16 Week Multi-Center, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Valsartan/Hydrochlorothiazide (HCTZ) Combination Therapy Compared to Patients Initiated With Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Very Elderly Patients With Essential Hypertension.

Next Previous
Trial Profile

A 16 Week Multi-Center, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Valsartan/Hydrochlorothiazide (HCTZ) Combination Therapy Compared to Patients Initiated With Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Very Elderly Patients With Essential Hypertension.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Aug 2011

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Valsartan/hydrochlorothiazide (Primary) ; Hydrochlorothiazide; Valsartan
  • Indications Essential hypertension; Hypertension
  • Focus Therapeutic Use
  • Acronyms VALVET
  • Sponsors Novartis; Novartis Pharmaceuticals

Most Recent Events

  • 21 Jun 2010 Results presented at the 20th European Meeting on Hypertension
  • 21 Jun 2010 Results presented at the 20th European Meeting on Hypertension.
  • 21 Jun 2010 Results presented at the 20th European Meeting on Hypertension.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top